Activity of OSE-2101 in HLA-A2+non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (IO): Final results of phase III Atalante-1 randomised trial
No Thumbnail Available
Identifiers
Date
2021-09-21
Authors
Besse, B.
Garcia Campelo, M. R.
Cobo Dols, M. A.
Quoix, E.
Madroszyk, A.
Felip, E.
Cappuzzo, F.
Denis, F.
Hilgers, W.
Romano, G.
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Metrics
Export
